Table 1 Metabolic parameters of non-fasted WD-fed MC4R-KO mice after CANA treatment for 8 and 20 weeks.

From: Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH

 

8 weeks

20 weeks

WT/SD

MC4R-KO/WD

MC4R-KO/WD/CANA

WT/SD

MC4R-KO/WD

MC4R-KO/WD/CANA

Insulin (ng/ml)

0.81 ± 0.13

9.98 ± 1.00

6.28 ± 0.98**

1.59 ± 0.24

10.05 ± 0.43

10.78 ± 0.61

Glucagon (pg/ml)

6.10 ± 0.90

10.77 ± 1.58

10.29 ± 2.53

8.91 ± 1.89

24.07 ± 5.44

26.34 ± 3.27

tGLP-1 (pg/ml)

15.00 ± 4.26

25.57 ± 4.28

31.21 ± 4.04

ND

ND

ND

aGLP-1 (pg/ml)

ND

ND

ND

4.06 ± 1.29

5.82 ± 0.68

7.55 ± 2.00

TG (mg/dl)

83.07 ± 6.30

116.92 ± 10.29

160.96 ± 18.98*

77.87 ± 7.02

64.96 ± 5.29

84.15 ± 7.44

NEFA (mEq/L)

0.39 ± 0.02

0.55 ± 0.03

0.61 ± 0.04

0.45 ± 0.03

0.53 ± 0.03

0.57 ± 0.04

  1. SD, standard diet; WD, western diet; CANA, Canagliflozin; tGLP-1, total GLP-1; aGLP-1, active GLP-1; TG, triglyceride; NEFA, non-esterified fatty acid. Data are mean ± SEM, *p < 0.05, **p < 0.01 vs MC4R-KO/WD; one-way ANOVA. n = 15.
Back to article page